Fennec Pharmaceuticals (NASDAQ:FENC) and GENFIT S A/ADR (NASDAQ:GNFT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Earnings and Valuation

This table compares Fennec Pharmaceuticals and GENFIT S A/ADR’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Fennec Pharmaceuticals N/A N/A -$12.77 million ($0.64) -8.84
GENFIT S A/ADR $8.85 million 58.31 -$93.91 million N/A N/A

Fennec Pharmaceuticals has higher earnings, but lower revenue than GENFIT S A/ADR.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Fennec Pharmaceuticals and GENFIT S A/ADR, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fennec Pharmaceuticals 0 0 2 0 3.00
GENFIT S A/ADR 0 1 5 0 2.83

Fennec Pharmaceuticals currently has a consensus price target of $16.50, suggesting a potential upside of 191.52%. GENFIT S A/ADR has a consensus price target of $51.25, suggesting a potential upside of 275.73%. Given GENFIT S A/ADR’s higher probable upside, analysts plainly believe GENFIT S A/ADR is more favorable than Fennec Pharmaceuticals.

Institutional and Insider Ownership

51.0% of Fennec Pharmaceuticals shares are held by institutional investors. Comparatively, 2.8% of GENFIT S A/ADR shares are held by institutional investors. 9.1% of Fennec Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


This table compares Fennec Pharmaceuticals and GENFIT S A/ADR’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fennec Pharmaceuticals N/A -81.68% -74.56%


GENFIT S A/ADR beats Fennec Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.


Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic test for the identification of patients with NASH; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.